Cholesterol Center, Jewish Hospital, Cincinnati, Ohio
|
|
- Cory Tate
- 5 years ago
- Views:
Transcription
1 HYPERANDROGENISM FERTILITY AND STERILITY VOL. 77, NO. 3, MARCH 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome C. J. Glueck, M.D., Ping Wang, Ph.D., Suichi Kobayashi, M.D., Harvey Phillips, M.D., and Luann Sieve-Smith Cholesterol Center, Jewish Hospital, Cincinnati, Ohio Objective: To assess whether metformin safely reduced development of gestational diabetes in women with the polycystic ovary syndrome (PCOS). Design: Prospective and retrospective study. Setting: Outpatient clinical research center. Patient(s): The prospective study included 33 nondiabetic women with PCOS who conceived while taking metformin and had live births; of these, 28 were taking metformin through delivery. The retrospective study included 39 nondiabetic women with PCOS who had live birth pregnancies without metformin therapy. Intervention(s): Metformin, 2.55 g/d, throughout pregnancy in women with PCOS. Main Outcome Measure(s): Development of gestational diabetes in women with PCOS. Result(s): Before metformin therapy, after covariance adjustment for age, the two cohorts did not differ in height, weight, basal metabolic index, insulin, insulin resistance, or insulin secretion. Both cohorts had high fasting insulin, were insulin resistant, and had high insulin secretion. Among the 33 women who received metformin, gestational diabetes developed in 1 of 33 (3%) pregnancies versus 8 of 12 (67%) of their previous pregnancies without metformin. Among the 39 women who did not take metformin, gestational diabetes developed in 14 of 60 (23%) pregnancies. When all live births were combined, gestational diabetes occurred in 22 of 72 pregnancies (31%) in women who did not take metformin versus 1 of 33 pregnancies (3%) in those who took metformin. With gestational diabetes as the response variable and age at delivery and treatment group (metformin or no metformin) as explanatory variables, the odds ratio for gestational diabetes in women with metformin versus without metformin was (95% CI: to 0.795). With gestational diabetes in 93 pregnancies as the response variable and age at delivery and treatment group (metformin no metformin) as explanatory variables, the odds ratio of gestational diabetes in pregnancies in women taking metformin versus without metformin was (95% CI: to 0.938). Conclusion(s): In PCOS, use of metformin is associated with a 10-fold reduction in gestational diabetes (31% to 3%). It also reduces insulin resistance and insulin secretion, thus decreasing the secretory demands imposed on pancreatic -cells by insulin resistance and pregnancy. (Fertil Steril 2002;77: by American Society for Reproductive Medicine.) Key Words: Gestational diabetes mellitus, polycystic ovary syndrome, pregnancy, insulin resistance Received May 22, 2001; revised and accepted October 5, Reprint requests: C. J. Glueck, M.D., Cholesterol Center, ABC Building, 3200 Burnet Avenue, Cincinnati, Ohio (FAX: ; glueckch@ healthall.com) /02/$22.00 PII S (01) Gestational diabetes mellitus (1) was detected in 3.52% of pregnancies in women years of age in a cross-sectional sample of live births in the United States (2). Gestational diabetes, which is related to increasing insulin resistance during pregnancy, is associated with increased later risk for type 2 diabetes (1). Risk factors for gestational diabetes include obesity, age, genetic background, and ethnicity (1, 2). Fetal macrosomia in gestational diabetes increases rates of birth trauma and cesarean section (3, 4). Diagnosis and management of gestational diabetes may reduce perinatal, neonatal, and long-term pediatric complications (1, 3, 4). Polycystic ovary syndrome (PCOS) affects 5% 10% of women (5 13). It is defined as the association of anovulation with clinical or biochemical hyperandrogenism in women with polycystic ovarian morphology on ultrasonog- 520
2 raphy (5 18). However, (U.S.) physicians have not uniformly accepted ovarian morphology as a diagnostic criterion. Women with PCOS are characterized by obesity, insulin resistance, and hyperinsulinemia (5 19), all of which are risk factors for gestational diabetes. Women in whom gestational diabetes develops are likely to have underlying polycystic ovaries (20 22), and women with PCOS are likely to develop gestational diabetes (19, 23 26). The insulin-sensitizing drug metformin is a safe, effective, and rational treatment for the metabolic and endocrine abnormalities in PCOS (5 13, 15). In women with type 2 diabetes, women with gestational diabetes (27), and nondiabetic patients with PCOS (15), metformin was not teratogenic and reduced the otherwise high (65%) likelihood (16) of first-trimester miscarriage in PCOS by 10-fold (15). Most women with gestational diabetes mellitus can be treated satisfactorily with diet alone. However, some require insulin or (experimentally) metformin or sulfonlyureas to achieve proper metabolic control (1, 3, 4, 27 29). We sought to determine whether metformin therapy safely reduced development of gestational diabetes in women with PCOS. MATERIALS AND METHODS Design and Participants This work was performed after obtaining signed informed consent from all participants, according to a protocol approved by the Jewish Hospital Institutional Review Board. We assessed 72 women with well-defined PCOS (6, 12 17) who had a mean ( SD) age of 34 8 years, were nondiabetic before their pregnancies, and had 1 live births. The development of gestational diabetes was studied prospectively in 33 women with PCOS who conceived while taking metformin, 2.55 g/d. Of these women, 28 took metformin throughout pregnancy. Thirty-four live births occurred. Development of gestational diabetes mellitus was studied retrospectively in 39 women with PCOS who had previously conceived without taking metformin; these women had 64 live births and information on gestational diabetes was available for 60 births. At baseline, pre metformin therapy and pre diet therapy height, weight, serum glucose and insulin level, insulin resistance, and insulin secretion were compared in two cohorts. At entry and at every 2-month follow-up visit, after an 8-hour overnight fast, weight, systolic and diastolic blood pressure, glucose, lipids, estradiol, progesterone, LH, FSH, androstenedione, DHEAS, testosterone, sex hormone binding globulin, serum insulin, and lactic acid were measured (6). Homeostasis model assessment (HOMA) formulae (30) were used to calculate insulin resistance and -cell function. At entry, 17-hydroxyprogesterone, prolactin, T 4, TSH, and cortisol were measured to rule out diseases that can mimic PCOS or affect its presentation (6, 17). In the prospective cohort, all women were instructed in a 1500-calorie/d, high-protein (26% of calories), low-carbohydrate (44%) diet, with 30% of calories as fat. After conception, calorie restrictions were dropped and continued adherence to the low-carbohydrate, high-protein diet was encouraged. Before and throughout pregnancy, folic acid (1 mg/d) was given. Patients with PCOS The diagnosis of PCOS (5 19) was based on the 1990 National Institutes of Health criteria (17): oligomenorrhea or amenorrhea, biochemical or clinical hyperandrogenism (31), or polycystic ovaries on ultrasonography and exclusion of disorders that mimic PCOS (17). Homeostasis model assessment insulin resistance (30) and hyperinsulinemia (6, 15, 32) were not required criteria for entry into the study. Exclusion criteria (6, 15) were serum creatinine level 1.5 mg/dl, other virilizing endocrinopathies, pituitary insufficiency, type 1 diabetes, and type 2 diabetes mellitus requiring pharmacologic therapy. Women taking drugs known to affect endogenous sex hormones or lipids and those taking valproic acid (33) in the 2 prestudy months were also excluded. Diagnosis of Gestational Diabetes Screening for gestational diabetes was done in conjunction with the patients obstetricians between the 26th and 28th weeks by using the criteria of the American Diabetes Association (34) and the National Diabetes Data Group s conversion of O Sullivan et al. s diagnostic criteria for the 100-g glucose challenge (35). Statistical Analysis Pretreatment height, weight, body mass index (BMI), glucose, insulin, insulin resistance, and insulin secretion in the two cohorts were compared after adjusting for age by analysis of variance (36). In the prospective cohort, levels before and during metformin therapy were compared by using paired nonparametric, Wilcoxon tests (36), since most of the data were not normally distributed. To compare gestational diabetes in the two cohorts, logistic regression analysis (36) was performed in which gestational diabetes (present or not present) was the response variable (70 women) and treatment (metformin or no metformin) and age at delivery (averaged age if a woman had 1 pregnancy) as the explanatory variables. A second logistic regression model assessed the odds ratio for gestational diabetes in pregnancies conceived during metformin therapy (n 33) versus those conceived without metformin therapy (60 pregnancies in 39 women). The response variable was gestational diabetes (yes or no) in 93 pregnancies, and the explanatory variables were treatment (metformin or no metformin) and age at delivery. The Fisher exact test (36) FERTILITY & STERILITY 521
3 was used to compare the frequency of gestational diabetes in women or pregnancies with or without metformin. Age- and sex-specific percentiles for height and weight in term neonates were assigned by using Centers for Disease Control and Prevention growth charts for the United States published in Sex- and gestational age specific percentiles for neonates born before 37 weeks of gestation were obtained from the study by Lubschenco et al. (37). In women with PCOS, percentile distributions of preconception BMI were determined by using age- and sex-specific data from normal Lipid Research Clinics samples (38). RESULTS Women With PCOS Who Conceived During Metformin Therapy and Had Live Births Of the 32 white women and 1 Latina who conceived while taking metformin and had live births, 18 (55%) were amenorrheic and 14 (42%) were oligomenorrheic in the year before our evaluation. Only 1 of 33 (3%) had 10 menses/y. By selection, these women had oligomenorrhea or amenorrhea, biochemical or clinical hyperandrogenism, or polycystic ovarian morphology on ultrasonography. Of these 33 women, 15 could not conceive before metformin therapy; 18 had 46 previous pregnancies without metformin, from which 12 live births (26%) and 34 miscarriages (74%) resulted. Gestational diabetes developed in 8 of these 12 previous pregnancies (67%) without metformin. In the current study, the mean duration of preconception metformin treatment in these 33 women was months (median, 5.8 months). Women With PCOS Who Previously Had Live Births Without Metformin Of the 37 white and 2 African-American women who had previous live births without metformin therapy, 21 (54%) were amenorrheic and 15 (38%) were oligomenorrheic. Three of 39 (8%) had 10 menses in the year before our evaluation. By selection, they had oligomenorrhea or amenorrhea, biochemical or clinical hyperandrogenism, or polycystic ovarian morphology on ultrasonography. These 39 women had 94 previous pregnancies without metformin therapy, resulting in 64 live births (68%), 26 miscarriages (28%), and 4 elective abortions. Studies for gestational diabetes had been done in 37 women in 60 of the 64 pregnancies resulting in live births, none of which was conceived or carried to term during metformin therapy. Insulin and Glucose Levels, HOMA Insulin Resistance, and HOMA -Cell Function Before Metformin Therapy At baseline before treatment, the 39 women in the retrospective study were older than the 33 women in the prospective study (mean [ SD], years vs years; P.0001), but at the time of delivery, the former cohort was younger ( years vs years). After covariance adjustment for age at baseline before treatment, the two cohorts did not differ in height, weight, BMI, fasting serum insulin level, insulin resistance, and insulin secretion (P.1 for all); the least-squares mean fasting glucose level was higher in the prospective cohort than the retrospective cohort (98 vs. 89 mg/dl; P.047). Both cohorts were very obese. The median weight was 90 kg and 89 kg and median BMI was 33.5 kg/m 2 and 33.6 kg/m 2 in the prospective and retrospective cohorts, respectively. Sixty-six percent of the 33 women in the prospective cohort and 54% of the 39 women in the retrospective cohort had BMI greater than or equal to the Lipid Research Clinics (38) age- and sex-specific 95th percentile. The fasting insulin level was high in the prospective and retrospective cohorts (median, 22 uu/ml and 19 uu/ml, respectively). Insulin resistance ( 90th percentile in 161 healthy normal women [5.54]) was present in 39% of the prospective cohort and in 36% of the retrospective cohort. -Cell function (insulin secretion) was high ( 361, the 90th percentile for 161 controls) in 36% and 28% of the prospective and retrospective cohorts, respectively. Development of Gestational Diabetes Gestational diabetes developed in 1 of 33 (3%) women who took metformin and in 10 of 37 (27%) without metformin (P.0074, Fisher test). Gestational diabetes developed in 1 of 33 pregnancies (3%) in the 33 women who took metformin versus 14 of 60 (23%) pregnancies in the 39 women who did not take metformin (P.016, Fisher test). When all live births without metformin were combined (gestational diabetes in 14 of 60 pregnancies in retrospective cohort and 8 of 12 previous pregnancies in the prospective cohort), gestational diabetes occurred in 22 of 72 pregnancies (31%) without metformin therapy and 1 of 33 pregnancies (3%) with metformin therapy (P.0009, Fisher test). In logistic regression analysis, after adjustment for age at delivery, the odds ratio for gestational diabetes in women who received metformin vs. those who did not receive metformin was (95% CI: to 0.795) (P.03). The odds ratio for gestational diabetes in pregnancies during metformin therapy versus those during no metformin therapy was (95% CI: to 0.938) (P.04). Gestational Age, Weight, and Height In Neonates of the Prospective Cohort The mean and median gestation of the 33 pregnancies in women taking metformin were and 39.7 weeks, respectively. Five women delivered before 37 weeks (1 each at 26, 29, and 33 weeks and 2 at 35 weeks). The distribution of height and weight in the 34 neonates (1 twin pair and 32 singleton births) closely approximated a normal distribution. For weight, 58% of neonates were in the bottom 50% of the distribution and 42% were in the top 50%. For height, 47% of neonates were in the bottom 50% of the distribution and 53% were in the top 50%. 522 Glueck et al. Metformin reduces gestational diabetes Vol. 77, No. 3, March 2002
4 Effects of Metformin In Weight, BMI, Insulin, Insulin Resistance, and Insulin Secretion In 21 of the 33 women who conceived while taking metformin, complete data was available for weight, BMI, insulin, insulin resistance, and insulin secretion. We compared values before metformin therapy with values at the last preconception visit while taking metformin. In these 21 women, median weight decreased from 94 to 88 kg (P.0001), BMI from 33.6 to 29.6 kg/m 2 (P.0001), insulin level from 23 to 14 uu/ml (P.001), insulin resistance from 5.33 to 2.87 (P.0005), and insulin secretion from 274 to 226 (P.04) after metformin therapy. In 15 women who received metformin throughout pregnancy, complete data were available before metformin therapy, baseline before pregnancy, at the last preconception visit during metformin therapy, at the first visit at 4 6 weeks of gestation during metformin therapy, and the mean of subsequent visits during pregnancy while taking metformin (Fig. 1). From baseline to the last visit while taking metformin before conception, median weight decreased from 102 to 88 kg (P.0001), BMI from 33.9 to 30.3 kg/m 2 (P.0001), insulin from 23 to 15 uu/ml (P.04), and insulin resistance from 4.82 to 3.18 (P.03) (Fig. 1). These effects were maintained without significant change (P 0.05) throughout pregnancy (Fig. 1). Maternal and Fetal Safety During Metformin Therapy Of the 33 women taking metformin, none developed lactic acidosis. Intermittent diarrhea or gastritis were common in the first 3 weeks of metformin therapy but resolved spontaneously and were not limiting factors. No major fetal malformations or fetal hypoglycemia occurred in the 34 live births. FIGURE 1 Median weight, body mass index (BMI), fasting serum insulin level, and insulin resistance (IR) in 15 women with the polycystic ovary syndrome before metformin therapy, at their last preconception evaluation during metformin therapy, at their first visit after conception during metformin therapy (4 6 weeks of gestation), and throughout the remainder of their pregnancy during metformin therapy. Paired Wilcoxon tests of difference were done to compare values at baseline with those at prepregnancy during metformin therapy, values at prepregnancy during metformin therapy with those at the first visit after conception during metformin therapy, and values at the first visit after conception during metformin therapy with those during remainder of pregnancy during metformin therapy). DISCUSSION In most (19, 26) but not all (39) studies, women with PCOS develop gestational diabetes more often than healthy women, 20% vs. 8.9% (19), and 41% vs. 3% (26). Moreover, of women without previously diagnosed PCOS who develop gestational diabetes, 44% to 52% have been reported subsequently to have polycystic ovarian morphology (20 22). In our study, the prevalence of gestational diabetes in pregnancies in women not taking metformin (31%) was comparable to that in previous reports (19, 23 26). The 3% prevalence of gestational diabetes in women taking metformin approximates that in the general population 3.52% (2) and represents a 10-fold reduction (31% to 3%) compared with pregnancies in women with PCOS who did not take metformin. The odds ratio for gestational diabetes mellitus was (95% CI: to 0.795) in women taking metformin versus those not taking metformin (P.03) and (95% CI: to 0.938) for pregnancies in women taking metformin versus those not taking metformin Glueck. Metformin reduces gestational diabetes. Fertil Steril (P.04). After covariance adjustment for age at delivery, metformin was associated with about a 10-fold reduction in the rate of gestational diabetes in women with PCOS. Gestational diabetes develops because pregnancy increases requirements for insulin secretion while increasing insulin resistance, which in turn increases demands on pancreatic -cells (1, 20 26). Before pregnancy, women with PCOS commonly have insulin resistance (5 13) and obesity, which are major risk factors for gestational diabetes (1, 2). Because they often have infertility (15, 16), women with PCOS are older than the general population at conception, which is another risk factor (2) for gestational diabetes. In agreement with previous reports (5 13), we found that before pregnancy, metformin and diet decreased weight, FERTILITY & STERILITY 523
5 BMI, insulin, insulin resistance, and insulin secretion; these decreases should reduce demands on the pancreatic -cells. In women taking metformin, these effects were maintained throughout pregnancy. Without caloric restriction during pregnancy, the median body weight of women taking metformin did not increase (P.1); this, along with the lowcarbohydrate diet (44% of calories), may have contributed (1) to reduced development of gestational diabetes. Women with gestational diabetes often have impaired pancreatic -cell compensation for insulin resistance (40). Troglitazone (another insulin-sensitizing drug) improves insulin sensitivity in women with gestational diabetes (41). It is not surprising that metformin therapy during pregnancy reduces the rate of gestational diabetes mellitus by 10-fold. We speculate that metformin, Like troglitazone (42), may protect pancreatic -cells from failure, thus decreasing the risk for developing type 2 diabetes mellitus later. Prevention of gestational diabetes mellitus reduces development of macrosomia, with its attendant neonatal morbidity and mortality (3, 4), and may reduce the risk for subsequent development of type 2 diabetes, which occurs more commonly in women with gestational diabetes than in those without the disease (1, 40, 41). If data from our study were used to design a blinded, placebo-controlled clinical trial, 102 live births (51 randomized to metformin and 51 to placebo) stratified by age and BMI will be required to have a 95% chance of showing that metformin decreases the development of gestational diabetes in women with PCOS (at P.05). In women who were diabetic before conception, Hellmuth et al. (43) reported that treatment with metformin during pregnancy was associated with an increased prevalence of preeclampsia (32% of women taking metformin vs. 7% of women taking sulfonylurea and 10% of women taking insulin) and higher perinatal mortality (11.6% of women taking metformin vs. 1.3% of women taking sulfonylurea or insulin). However, our pilot data (15, 44) for women with PCOS and those of Coots and Jackson (27) for diabetic women and nondiabetic women with gestational diabetes point to the safety and pregnancy-enhancing efficacy of metformin. References 1. Butte NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr 2000; 71(Suppl):1256S 61S. 2. Engelgau MM, Herman WH, Smith PJ, German RR, Aubert RE. The epidemiology of diabetes and pregnancy in the US, Diabetes Care 1995;18: Hod M, Bar J, Peled Y. Antepartum management protocol: timing and mode of delivery in women with gestational diabetes. Diabetes Care 1998;21(Suppl 2): B Persson B, Hanson U. Neonatal morbidities in gestational diabetes mellitus. Diabetes Care 1998;21(Suppl 2):B Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138: Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformininduced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with polycystic ovary syndrome. Metabolism 1999;48: Moghetti P, Castello R, Negri C, Tosi F, Perrone B, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85: Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69: Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338: Nestler JE, Jakubowicz D. Decrease in ovarian cytochrome P450C17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335: Velazquez EM, Mendoza SG, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43: Velazquez EM, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90: Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with decreased plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with polycystic ovary syndrome. Metabolism 1997;46: Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism Br J Med 1986;293: Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001;75: Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999;48: Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR (eds). Polycystic ovary syndrome. Cambridge, MA: Blackwell Scientific, 1992; Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132: Mikola M, Hiilesmaa V, Hailttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001;16: Anttila L, Karjala K, Penttila RA, Ruutiainen K, Ekblad U. Polycystic ovaries in women with gestational diabetes. Obstet Gynecol 1998;92: Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998;84: Kousta E, Cela E, Lawrence N, Penny A, Millauer B, White D, et al. The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin Endocrinol (Oxf) 2000;53: Lanzone A, Caruso A, Di Simone N, De Carolis S, Fulghesu AM, Mancuso S. Polycystic ovary disease. A risk factor for gestational diabetes? J Reprod Med 1995;40: Lesser KB, Garcia FA. Association between polycystic ovary syndrome and glucose intolerance during pregnancy. J Matern Fetal Med. 1997; 6: Paradisi G, Fughesu AM, Ferrazzani S, Moretti S, Ptoro C, Soranna L, et al. Endocrino-metabolic features in women with polycystic ovary syndrome during pregnancy. Hum Reprod 1998;13: Radon PA, McMahon MJ, Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Diabetologia 1999; 94: Coetzee EJ, Jackson WPU. Metformin in management of pregnant insulin-independent diabetes. Diabetologia 1979;16: Stowers JM, Sutherland HW. The use of sulfonylureas, biguanides and insulin in pregnancy. In: Sutherland HW, Stowers JM (eds). Carbohydrate metabolism in pregnancy and the new-born. New York: Churchill Livingstone, 1975; Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;394: Haffner SM, Gonzalez C, Miettinen H, Kennedy E, Stern M. A pro- 524 Glueck et al. Metformin reduces gestational diabetes Vol. 77, No. 3, March 2002
6 spective analysis of the HOMA model. Diabetes Care 1996;19: Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21: Glueck CJ, Lang JE, Tracy T, Sieve-Smith L, Wang P. Contribution of fasting hyperinsulinemia to prediction of atherosclerotic disease status in 293 hyperlipidemic patients. Metabolism 1999;48: Isojarvi JI, Ratta J, Myllyla VV, Knip M, Knivunen R, Pakarinene AJ, et al: Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43: Position statement -gestational diabetes. American Diabetes Association. Diabetes Care 1986;9: O Sullivan JB, Mahan CM, Charles D, Dandrow R. Screening criteria for high-risk gestational diabetic patients. Am J Obstet Gynecol 1973; 116: Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames, IA: Iowa State University Press, Lubschenco L, Hansman C, Boyd E. Intrauterine growth in length and head circumference as estimated from live births at gestational ages from 26 to 42 weeks. Pediatrics 1966;37: The Lipid Research Clinics Population Studies Data Book. The prevalence study. Vol 1. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, NIH publication , Bethesda, MD. 39. Vollenhoven B, Clark S, Kovacs G, Burger H, Healy D. Prevalence of gestational diabetes mellitus in polycystic ovarian syndrome (PCOS) patients pregnant after ovulation induction with gonadotrophins. Aust N Z J Obstet Gynaecol 2000;40: Xiang AH, Peters RK, Trigo E, Kjos SL, Lee WP, Buchanan TA. Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes. Diabetes 1999;48: Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A, et al. Response of pancreatic beta cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 2000; 49: Buchanan TA, Peters RK, Xiang ST, Kjos A, Marroquin A, Goico J, et al: Prevention of type 2 diabetes by treatment of insulin resistance [abstract]. J Invest Med 2001;49:191A. 43. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycemic agents in 118 diabetic pregnancies. Diabet Med 2000;17: Glueck CJ, Sieve-Smith L, Wang P. Metformin improves pregnancy outcomes in 143 women with polycystic ovary syndrome [abstract]. J Invest Med 2001;49:194A. FERTILITY & STERILITY 525
Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Pregnancies following
More informationPregnancy outcomes among women with polycystic ovary syndrome treated with metformin
Human Reproduction Vol.17, No.11 pp. 2858 2864, 2002 Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin Charles J.Glueck 1, Ping Wang, Naila Goldenberg and Luann Sieve-Smith
More informationPOLYCYSTIC OVARY SYNDROME
POLYCYSTIC OVARY SYNDROME FERTILITY AND STERILITY VOL. 75, NO. 1, JANUARY 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in
More informationDiabetic Medicine. Myo-inositol may prevent gestational diabetes in PCOS women. Preliminary data.
Myo-inositol may prevent gestational diabetes in PCOS women. Preliminary data. Journal: Diabetic Medicine Manuscript ID: DME--00 Manuscript Type: Short Report Date Submitted by the Author: -May- Complete
More informationPregnancy outcome in women with polycystic ovary syndrome
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Nivedhitha VS et al. Int J Reprod Contracept Obstet Gynecol. 2015 Aug;4(4):1169-1175 www.ijrcog.org pissn 2320-1770 eissn
More informationPregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., and Elizabeth M. Jackson, B.S. Center for Applied Reproductive Science,
More informationMetformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice
Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice N. D. C. Sturrock, 1 B. Lannon 2 & T. N. Fay 2 Departments of 1 Endocrinology and 2
More informationGestational Diabetes. Gestational Diabetes:
Gestational Diabetes Detection and Management Steven Gabbe, MD The Ohio State University Medical Center Gestational Diabetes: Detection and Management Learning Objectives: At the conclusion of this presentation,
More informationThe effect of metformin on hirsutism in polycystic ovary syndrome
European Journal of Endocrinology (2002) 147 217 221 ISSN 0804-4643 CLINICAL STUDY The effect of metformin on hirsutism in polycystic ovary syndrome Christopher J G Kelly and Derek Gordon Stobhill Hospital,
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationPolycystic Ovary Syndrome
What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular
More informationMetformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 69, NO. 4, APRIL 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Metformin therapy improves
More informationReproductive outcome in women with body weight disturbances
Reproductive outcome in women with body weight disturbances Zeev Shoham M.D. Dep. Of OB/GYN Kaplan Hospital, Rehovot, Israel Weight Status BMI (kg/m 2 ) Underweight
More informationPregnancy complications and glucose intolerance in women with polycystic ovary syndrome
Endocrine Journal 2015, 62 (11), 1017-1023 Original Pregnancy complications and glucose intolerance in women with polycystic ovary syndrome Mari Sawada, Hisashi Masuyama, Kei Hayata, Yasuhiko Kamada, Keiichiro
More informationMetformin in early pregnancy and abortions. Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland
Metformin in early pregnancy and abortions Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland PCOS and miscarriage risk Metformin and miscarriage risk
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More informationDetermining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)
Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.
More informationVishwanath Pattan Endocrinology Wyoming Medical Center
Vishwanath Pattan Endocrinology Wyoming Medical Center Disclosure Holdings in Tandem Non for this Training Introduction In the United States, 5 to 6 percent of pregnancies almost 250,000 women are affected
More informationMETFORMIN A CONVENIENT ALTERNATIVE TO INSULIN FOR INDIAN WOMEN WITH DIABETES IN PREGNANCY
491 METFORMIN A CONVENIENT ALTERNATIVE TO INSULIN FOR INDIAN WOMEN WITH DIABETES IN PREGNANCY ABSTRACT LAVANYA RAI, MEENAKSHI D, ASHA KAMATH 1 OBJECTIVE: To compare the use of metformin with that of insulin
More informationManagement of Pregestational and Gestational Diabetes Mellitus
Background and Prevalence Management of Pregestational and Gestational Diabetes Mellitus Pregestational Diabetes - 8 million women in the US are affected, complicating 1% of all pregnancies. Type II is
More informationOriginal Article Pregnancy Complications - Consequence of Polycystic Ovary Syndrome or Body Mass Index?
Chettinad Health City Medical Journal Original Article Puvithra T*, Radha Pandiyan**, Pandiyan N*** *Assistant Professor, **Senior Consultant & Associate Professor, ***Prof & HOD, Department of Andrology
More informationOral Agents Revised 2006:
Oral Agents Revised 2006: Use of oral agents for glycemic control during pregnancy complicated by GDM Over the past few years, oral agents have been reintroduced in the management of diabetes during pregnancy.
More informationThe prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria
Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based
More informationCREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University
CREATING A PCOS TREATMENT PLAN Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University PCOS: CREATING A TREATMENT PLAN Good treatment plans are based on sound and complete evaluations History of
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationPolycystic ovary syndrome
OBG MANAGEMENT COVER ARTICLE Polycystic ovary syndrome 3 key challenges BY DALE W. STOVALL, MD Newer findings have broadened options for medical management of insulin resistance, anovulation, and hyperandrogenism.
More information3. Metformin therapy for PCOS
1. Introduction The key clinical features of polycystic ovary syndrome (PCOS) are hyperandrogenism (hirsutism, acne, alopecia) and menstrual irregularity with associated anovulatory infertility. 1 The
More informationThe Impact of Insulin Resistance on Long-Term Health in PCOS
Saturday, April 16 th, 2016 PCOS Challenge & Thomas Jefferson University PCOS Awareness Symposium Philadelphia The Impact of Insulin Resistance on Long-Term Health in PCOS Katherine Sherif, MD Professor
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationSemih Tugrul, M.D., Tayfun Kutlu, M.D., Oya Pekin, M.D., Elif Baglam, M.D., H useyin Kıyak, M.D., and Ozay Oral, M.D.
Clinical, endocrine, and metabolic effects of acarbose, a a-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome Semih Tugrul, M.D., Tayfun Kutlu, M.D., Oya
More informationDepartment of Obstetrics and Gynecology, University of Modena, Modena, Italy
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Metformin administration modulates
More informationMETABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationNew PCOS guidelines: What s relevant to general practice
New PCOS guidelines: What s relevant to general practice Dr Michael Costello Fertility Specialist IVF Australia UNSW Royal Hospital for Women Sydney How do we know if something is new? Louvre Museum, Paris
More informationMetformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study
The Journal of Obstetrics and Gynecology of India (September-October 2012) 62(5):551 556 DOI 10.1007/s13224-012-0183-3 ORIGINAL ARTICLE Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative
More informationPolycystic Ovary Disease: A Common Endocrine Disorder in Women
Polycystic Ovary Disease: A Common Endocrine Disorder in Women Paul Kaplan, M.D. Clinical Professor of Reproductive Endocrinology - OHSU Courtesy Senior Research Associate, Human Physiology University
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More informationPCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS
PCOS Awareness Symposium Atlanta September 24 th, 2016 Preventing Diabetes & Cardiovascular Disease in PCOS Katherine Sherif, MD Professor & Vice Chair, Department of Medicine Director, Jefferson Women
More informationJannet Huang, MD, FRCPC, FACE, ABIHM, CCD, NCMP.
Jannet Huang, MD, FRCPC, FACE, ABIHM, CCD, NCMP. Polycystic Ovarian Syndrome Definition & Diagnosis Clinical Significance: Link to Diabetes and Cardiovascular Risk Management Lifestyle Strategies Pharmacologic
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationMetformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome
IJMS Vol 36, No 2, June 2011 Original Article Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome Marzieh Farimani Sanoee 1, Nosrat Neghab 1, Soghra
More informationPolycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology
Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about
More informationInfertility: A Generalist s Perspective
Infertility: A Generalist s Perspective Learning Objectives Fertility and Lifestyle: Patient education Describe the basic infertility workup Basic treatment strategies unexplained Heather Huddleston, MD
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationGestational Diabetes. Benjamin Byers, D.O., FACOG Center for Maternal and Fetal Care Bryan Physician Network
Gestational Diabetes Benjamin Byers, D.O., FACOG Center for Maternal and Fetal Care Bryan Physician Network Outline Definition Prevalence Risk factors complications Diagnosis Management Nonpharmacologic
More informationMETABOLIC SYNDROME IN REPRODUCTIVE FEMALES
METABOLIC SYNDROME IN REPRODUCTIVE FEMALES John J. Orris, D.O., M.B.A Division Head, Reproductive Endocrinology & Infertility, Main Line Health System Associate Professor, Drexel University College of
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationRISK OF EARLY & LATE OBSTETRIC COMPLICATIONS IN WOMEN WITH IVF- CONCEIVED PREGNANCIES AND POLYCYSTIC OVARY SYNDROME (PCOS)
RISK OF EARLY & LATE OBSTETRIC COMPLICATIONS IN WOMEN WITH IVF- CONCEIVED PREGNANCIES AND POLYCYSTIC OVARY SYNDROME (PCOS) N. A. Bagegni, BS 1, J Blaine, BS 1, B J VanVoorhis, MD 1, A Dokras, MD.PhD 2
More informationThe role of metformin in the treatment of infertile women with polycystic ovary syndrome
The role of metformin in the treatment of infertile women with polycystic ovary syndrome Anju Sinha and William Atiomo 10.1576/toag.6.3.145.26996 www.rcog.org.uk/togonline Keywords infertility, metformin,
More informationDiabetes in Pregnancy
JSAFOG Diabetes in Pregnancy CONTEMPORARY REVIEW ARTICLE Diabetes in Pregnancy Neeta Deshpande Consultant, Diabetologist and Bariatric Physician, Belgaum Diabetes Center, Belgaum, Karnataka, India Correspondence:
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationPolycystic ovarian syndrome Can lifestyle modifications help?? Dr Saloni Assistant Professor, Deptt of OBG BPSGMC for Women, Khanpur Kalan
Polycystic ovarian syndrome Can lifestyle modifications help?? Dr Saloni Assistant Professor, Deptt of OBG BPSGMC for Women, Khanpur Kalan Life-long condition Hirsutism Menstrual irregularities? Pronounced
More informationDoes free androgen index predict subsequent pregnancy outcome in women with recurrent miscarriage?
Human Reproduction Vol.23, No.4 pp. 797 802, 2008 Advance Access publication on February 8, 2008 doi:10.1093/humrep/den022 Does free androgen index predict subsequent pregnancy outcome in women with recurrent
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationThe Pharmacology of PCOS
The Pharmacology of PCOS G. Wright Bates, Jr., M.D. Director Reproductive Endocrinology & Infertility University of Alabama at Birmingham Objectives Review the diagnosis of PCOS Highlight lifestyle modifications
More informationReceived: Accepted:
Received: 4.4.2011 Accepted: 11.6.2011 Original Article The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More informationPCOS and Your Fertility. Jim Toner, MD, PhD Atlanta Center for Reproductive Medicine
PCOS and Your Fertility Jim Toner, MD, PhD Atlanta Center for Reproductive Medicine PCOS Consequences Androgen excess Acne, oily skin Unwanted hair, male pattern baldness Insulin excess Diabetes, heart
More informationComparative study of metabolic profile of women presenting with polycystic ovary syndrome in relation to body mass index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Akshaya S et al. Int J Reprod Contracept Obstet Gynecol. 2016 Aug;5(8):2561-2565 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More information2/13/2018. Update on Gestational Diabetes. Disclosure. Objectives. I have no financial conflicts of interest.
Update on Gestational Diabetes Lorie M. Harper, MD, MSCI Department of Obstetrics & Gynecology Division of Maternal-Fetal Medicine 2/18/2018 Disclosure I have no financial conflicts of interest. Objectives
More informationA CLINICAL STUDY OF GESTATIONAL DIABETES MELLITUS IN A TEACHING HOSPITAL IN KERALA Baiju Sam Jacob 1, Girija Devi K 2, V.
A CLINICAL STUDY OF GESTATIONAL DIABETES MELLITUS IN A TEACHING HOSPITAL IN KERALA Baiju Sam Jacob 1, Girija Devi K 2, V. Baby Paul 3 HOW TO CITE THIS ARTICLE: Baiju Sam Jacob, Girija Devi K, V. Baby Paul.
More informationLONG OR HIGHLY IRREGULAR MENstrual
ORIGINAL CONTRIBUTION Long or Highly Irregular Menstrual Cycles as a Marker for Risk of Type 2 Diabetes Mellitus Caren G. Solomon, MD Frank B. Hu, MD Andrea Dunaif, MD Janet Rich-Edwards, DSci Walter C.
More informationHow Metformin Acts in PCOS Pregnant Women
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E How Metformin Acts in PCOS Pregnant Women Insights in insulin secretion and peripheral action at each trimester of
More informationThe contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome
Human Reproduction vol.14 no.2 pp.307 311, 1999 The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome E.Carmina 1, F.Gonzalez 2, A.Vidali
More informationScreening and Diagnosis of Diabetes Mellitus in Taiwan
Screening and Diagnosis of Diabetes Mellitus in Taiwan Hung-Yuan Li, MD, MMSc, PhD Attending Physician, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan Associate Professor,
More informationInsulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome
European Journal of Endocrinology (2001) 144 509±515 ISSN 0804-4643 CLINICAL STUDY Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More information2018 Standard of Medical Care Diabetes and Pregnancy
2018 Standard of Medical Care Diabetes and Pregnancy 2018 Standard of Medical Care Diabetes and Pregnancy Marjorie Cypress does not have any relevant financial relationships with any commercial interests
More informationMetformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study
Human Reproduction Vol.19, No.8 pp. 1734 1740, 2004 Advance Access publication June 3, 2004 DOI: 10.1093/humrep/deh347 Metformin reduces pregnancy complications without affecting androgen levels in pregnant
More informationThe New GDM Screening Guidelines. Jennifer Klinke MD, FRCPC Endocrinologist and Co director RCH Diabetes in Pregnancy Program
The New GDM Screening Guidelines Jennifer Klinke MD, FRCPC Endocrinologist and Co director RCH Diabetes in Pregnancy Program Disclosures Current participant (RCH site) for MiTy study Metformin in women
More informationROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME
ORIGINAL ARTICLE ROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME 1 2 3 Samdana Wahab, Farnaz, Rukhsana Karim ABSTRACT Objective: To assess the role of Metformin in Polycystic ovarian syndrome (PCOS).
More informationPOLYCYSTIC OVARY SYNDROME
POLYCYSTIC OVARY SYNDROME Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome
More informationWhat every dermatologist should know about Polycystic Ovary Syndrome (PCOS)
What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) Kanade Shinkai, MD PhD University of California, San Francisco Associate Professor of Dermatology I have no conflicts of interest
More informationAmenorrhoea: polycystic ovary syndrome
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationPrevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai
Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai Principal Investigator Co- Investigators Consultant Collaborating Hospital Dr. Beena Joshi Dr. Srabani Mukherji
More informationMaximizing the Role of WIC Nutritionists in Prevention of DM2 among High Risk Clients ESTHER G. SCHUSTER, MS,RD,CDE
Maximizing the Role of WIC Nutritionists in Prevention of DM2 among High Risk Clients ESTHER G. SCHUSTER, MS,RD,CDE Heavy Numbers Surgeon General report: 68% of adults in U. S. are overweight or obese
More informationAbstract. Introduction. RBMOnline - Vol 10. No Reproductive BioMedicine Online; on web 15 November 2004
RBMOnline - Vol 10. No 1. 2005 100-104 Reproductive BioMedicine Online; www.rbmonline.com/article/1484 on web 15 November 2004 Article Metformin monotherapy in lean women with polycystic ovary syndrome
More informationPOLYCYSTIC OVARIAN SYNDROME WHERE WE ARE AT IN 2018
POLYCYSTIC OVARIAN SYNDROME WHERE WE ARE AT IN 2018 PCOS: WHERE WE ARE AT IN 2018 Nancy Arquette, MD Premier Women s Health 6135 Trust Drive #114 Holland, OH 43528 February 3, 2018 Kalahari Resorts ME
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationThe New England Journal of Medicine OVULATORY AND METABOLIC EFFECTS OF D-CHIRO-INOSITOL IN THE POLYCYSTIC OVARY SYNDROME
OVULATORY AND METABOLIC EFFECTS OF D-CHIRO-INOSITOL IN THE POLYCYSTIC OVARY SYNDROME JOHN E. NESTLER, M.D., DANIELA J. JAKUBOWICZ, M.D., PAULA REAMER, M.A., RONALD D. GUNN, M.S., AND GEOFFREY ALLAN, PH.D.
More informationThe prevalence of polycystic ovaries in healthy women
Acta Obstet Gynecol Scand 1999; 78: 137 141 Copyright C Acta Obstet Gynecol Scand 1999 Printed in Denmark all rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationPrevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study
Original Article Prevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study Majid Jahangir, MD 1 Seema Qayoom, MD ² Peerzada
More informationGestational Diabetes: An Update on Testing. Kimberlee A McKay, M.D. Avera Medical Group Ob/GYN
Gestational Diabetes: An Update on Testing Kimberlee A McKay, M.D. Avera Medical Group Ob/GYN Gestational Diabetes Increased risks of: Still Birth Hydramnios Should Dystocia Prolonged Labor Preeclampsia
More informationFemale Reproductive Endocrinology
Female Reproductive Endocrinology Dr. Channa Jayasena PhD MRCP FRCPath Clinical Senior Lecturer & Consultant Endocrinologist Department of Gynaecology, Hammersmith Hospital Anovulation is a common cause
More informationInsulin resistance and fertility in polycystic ovary syndrome
Insulin resistance and fertility in polycystic ovary syndrome Simona Fica *,**, Alice Albu **, Mădălina Constantin **, Georgiana Alina Dobri ** * Carol Davila University of Medicine and Pharmacy, Bucharest,
More informationORIGINAL ARTICLE. COMPARISON OF METFORMIN AND PIOGLITAZONE IN PCOS Archana V. Rokade, Javdekar D. P, Patange R. P.
COMPARISON OF METFORMIN AND PIOGLITAZONE IN PCOS Archana V. Rokade, Javdekar D. P, Patange R. P. 1. Assistant Professor. Department of Obstetrics & Gynaecology, Krishna Institute of Medical Sciences &
More informationWhat Degree of Maternal Metabolic Control in Women With Type 1 Diabetes Is Associated With Normal Body Size and Proportions in Full-Term Infants?
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E What Degree of Maternal Metabolic Control in Women With Type 1 Diabetes Is Associated With Normal Body Size and Proportions in Full-Term
More informationCLINICAL, BIOCHEMICAL AND ULTRASONOGRAPHIC FEATURES OF INFERTILE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME
ORIGINAL ARTICLE CLINICAL, BIOCHEMICAL AND ULTRASONOGRAPHIC FEATURES OF INFERTILE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME Fauzia Haq, Omar Aftab* and Javed Rizvi ABSTRACT Objective: To evaluate and compare
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationPOLYCYSTIC ovary syndrome (PCOS) appears to be a
0021-972X/99/$03.00/0 Vol. 84, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society A Survey of the Polycystic Ovary Syndrome in the Greek
More informationInfertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery
Macut D, Pfeifer M, Yildiz BO, Diamanti-Kandarakis E (eds): Polycystic Ovary Syndrome. Novel Insights into Causes Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications
More informationPregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes
Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes Stefano Palomba, M.D., a Angela Falbo, M.D., a Tiziana Russo, M.D.,
More informationProblems in PCOS pregnancy
Problems in PCOS pregnancy Miscarriage Admission to NICU Cesarean Section Preeclampsia Mother Prematurity Preterm labour PIH Perinatal mortality Gestational Diabetes Problems with PCOS Pregnancy Problems
More informationIntroduction. Original Article
Iran J Reprod Med Vol. 10. No. 4. pp: 307-314, July 2012 Original Article Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women
More informationWhat is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this...
PCOS What is PCOS? You'll be amazed when you read this... What is PCOS?. Who is at risk? How to get tested? What are the complications. Is there a cure? What are the right ways to eat? What lifestyle changes
More informationManipal & Apollo Spectra Hospital. Special Interest:Laparoscopy & Bariatric Surgery
Name: Dr M G Bhat Designation: Consultant Surgeon Affiliation: Manipal & Apollo Spectra Hospital Special Interest:Laparoscopy & Bariatric Surgery When should we suggest Bariatric Surgery in PCOD? 17 June
More information